Acadia Pharmaceuticals

Company snapshot

Acacia Pharma, Inc. is a commercially driven hospital pharmaceutical group focused on the development and commercialization of new nausea and vomiting treatments for surgical and cancer patients. The Company has identified important and commercially attractive unmet needs in nausea and vomiting and has discovered two product candidates based on the same active ingredient, amisulpride, to meet thos

• 3 approved product(s) across US/EU regulatory metadata.
• 32 active pipeline program(s) linked via ClinicalTrials.gov.
• 77 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Acadia Pharmaceuticals. Not investment advice.

• approval Jun 4, 2026

  CHMP Negative Opinion on Acadia's Rett Syndrome Drug: Implications for Investors and Pharma Teams

• Peer + 0 momentum

  H. Lundbeck A/S

  TA overlap score 23.4

• Peer + 0 momentum

  Amneal Pharma Europe

  TA overlap score 23

Recent activity

Latest pipeline, patent, and corporate events for Acadia Pharmaceuticals.

1. Jun 8, 2026 Clinical update

   Placebo — Phase 3

2. Jun 8, 2026 Clinical update

   Pimavanserin — Phase 2

3. Jun 8, 2026 Clinical update

   pimavanserin tartrate — Phase 3

4. Jun 8, 2026 Clinical update

   Pimavanserin tartrate — Phase 2

5. Jun 8, 2026 Clinical update

   Pimavanserin tartrate (ACP-103) — Phase 3

View all clinical trial activity →

• What is Acadia Pharmaceuticals?

  Acadia Pharmaceuticals is a pharma organization headquartered in Indianapolis, USA. It trades on NYSE under ticker ACAD. Primary therapeutic focus areas include Schizophrenia, Alzheimer's Disease Psychosis, Parkinson Disease, Agitation and Aggression in Alzheimer's Disease, Parki

• Is Acadia Pharmaceuticals publicly traded?

  Yes. Acadia Pharmaceuticals is listed with ticker ACAD on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Acadia Pharmaceuticals develop or market?

  We link 15 drug profile(s) where Acadia Pharmaceuticals is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/acadia-pharmaceuticals-inc#company-drugs.

• What are the latest developments for Acadia Pharmaceuticals?

  In the last 12 months our linked public records show 32 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Acadia Pharmaceuticals focus on?

  Acadia Pharmaceuticals focuses on Schizophrenia, Alzheimer's Disease Psychosis, Parkinson Disease based on our analysis of their pipeline programs and drug development activities.